Autolus Therapeutics plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AUTL research report →
Range $7.6 – $11
Price Chart
About the company
Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is in a Phase 1 study for pediatric patients experiencing relapsed or refractory ALL.
- CEO
- Christian Martin Itin
- IPO
- 2018
- Employees
- 752
- HQ
- London, GL, GB
Get TickerSpark's AI analysis on AUTL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $389.90M
- P/E
- -1.34
- Fwd P/E
- 13.73
- PEG
- 0.05
- P/S
- 4.21
- P/B
- 3.58
- EV/EBITDA
- -1.47
- Div Yield
- 0.00%
- Gross Margin
- -11.19%
- Op Margin
- -285.90%
- Net Margin
- -311.95%
- ROE
- -128.53%
- ROIC
- -56.74%
Latest fiscal year · YoY change
- Revenue
- $75.56M+646.7%
- Gross Profit
- $-21,030,029+83.9%
- Op Income
- $-281,437,148
- Net Income
- $-288,199,915-30.6%
- EPS
- $-1.08-24.1%
- OCF Growth
- -37.5%
- FCF Growth
- -28.9%
- 52W High
- $2.70
- 52W Low
- $1.18
- 50D MA
- $1.60
- 200D MA
- $1.54
- Beta
- 2.03
- RSI (14)
- 44
- Avg Volume
- 1.39M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Get the AUTL Q1 '26 earnings-call summary
Create a free account to generate an AI summary of this call — key takeaways, results & guidance, CEO/CFO commentary, Q&A, and a bull vs bear read. Ready in about a minute, and it'll be live for everyone.
Create free account →Already have an account? Log in
- Free Float
- 90.4%
- Shares Outstanding
- 266.14M
- Float Shares
- 240.52M
of shares held by institutions
92 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Mak Capital One LLC | 33.62M | ▲ 3.62M |
| Blackstone Inc. | 20.49M | 0 |
| Syncona Portfolio Ltd | 16.64M | 0 |
| Armistice Capital, LLC | 15.80M | ▼ 1.70M |
| Tfg Asset Management Gp Ltd | 9.50M | 0 |
| Schroder Investment Management Group | 9.49M | 0 |
| Frazier Life Sciences Management, L.P. | 4.45M | ▼ 175.41K |
| Bnp Paribas Asset Management Holding S.A. | 3.36M | 0 |
| Axa Investment Managers S.A. | 3.36M | ▲ 3.36M |
| Laurion Capital Management LP | 3.32M | 0 |
| Renaissance Technologies LLC | 2.30M | ▼ 805.90K |
| Bank Of America Corp | 1.84M | ▼ 116.09K |
Held by 18 ETFs
Biggest fund positions in AUTL by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 29, 26 | YOUNG WILLIAM D | other | 47,500 |
| Jun 29, 26 | YOUNG WILLIAM D | other | 31,667 |
| Jun 29, 26 | Rao Madduri Ravin | other | 47,500 |
| Jun 29, 26 | Rao Madduri Ravin | other | 31,667 |
| Jun 29, 26 | Richardson Ryan | other | 47,500 |
| Jun 29, 26 | Richardson Ryan | other | 31,667 |
| Jun 29, 26 | Leiderman Elisabeth | other | 47,500 |
| Jun 29, 26 | Leiderman Elisabeth | other | 31,667 |
| Jun 29, 26 | Iannone Robert | other | 47,500 |
| Jun 29, 26 | Iannone Robert | other | 31,667 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our AUTL coverage
Recent articles, reports, and earnings notes.
Want a deeper read on AUTL?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
3 Cancer Stocks to Watch as Oncology Innovation Accelerates
zacks.com · Jul 8
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Jul 1
Autolus Therapeutics to Participate in Upcoming Investor Conference
globenewswire.com · Jun 25
Autolus Therapeutics Receives Prix Galien UK Award
globenewswire.com · Jun 12
Autolus Therapeutics (AUTL) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
zacks.com · Jun 10
Autolus Therapeutics PLC Sponsored ADR (AUTL) Just Flashed Golden Cross Signal: Do You Buy?
zacks.com · Jun 1
Autolus Therapeutics to Participate in Upcoming Investor Conferences
globenewswire.com · May 27
Autolus Therapeutics to Present Clinical Data Update at the American Society of Clinical Oncology Annual Meeting 2026
globenewswire.com · May 21
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
Bullish or bearish?
Where do you stand on AUTL?